杜皮鲁玛
医学
持久性(不连续性)
特应性皮炎
皮肤病科
年轻人
免疫学
疾病严重程度
梅德林
免疫病理学
入射(几何)
儿科
抗体
作者
J. Morel Symons,Janis L. Breeze,Stevan Geoffrey Severtson,Stefan C Weiss,Dharm S. Patel
摘要
BACKGROUND: Dupilumab has demonstrated benefits in patients with atopic dermatitis (AD), but there is limited information on real-world rates of dupilumab persistence and supplementation with topical and systemic treatments beyond adult populations. OBJECTIVE: This retrospective cohort study evaluated real-world dupilumab use among children (<13 years), adolescents (13–17 years), and adults (≥18 years) with moderate-to-severe AD, who initiated dupilumab (March 2017 to September 2021) in the United States. METHODS: The OM1 PremiOM™ AD dataset was used to assess dupilumab treatment persistence and treatment supplementation over a 24-month period. RESULTS: Of 5200 eligible patients who initiated dupilumab, 208 were children, 430 were adolescents, and 4562 were adults. Dupilumab persistence decreased consistently over 24 months of follow-up. The probability of dupilumab persistence at 12 and 24 months was 79.8% and 70.8% in children, 81.9% and 63.1% in adolescents, and 73.2% and 55.7% in adults, respectively. Across all patients, treatment supplementation increased over time; 31.5% received supplemental systemic therapy, and 62.1% received topical medications at 24 months. CONCLUSIONS: Over a 2-year period, dupilumab persistence generally decreased while treatment supplementation increased for all patient groups, indicating a considerable proportion of patients with AD have unaddressed treatment needs.
科研通智能强力驱动
Strongly Powered by AbleSci AI